期刊
CNS SPECTRUMS
卷 15, 期 6, 页码 394-404出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852900029266
关键词
-
资金
- Bristol-Myers Squibb
- Eli Lilly
- Takeda
- Agency for Healthcare Research and Quality
- National Institute of Mental Health (NIMH)
- Novartis
- M-3 Corporation
- Abbott
- Alkermes
- Aspect Medical Systems
- AstraZeneca
- Cephalon
- Forest Pharmaceuticals
- Ganeden
- GlaxoSmithKline
- Johnson Johnson
- Lichtwer Pharma GmbH
- Lorex
- National Alliance for Research in Schizophrenia and Depression (NARSAD)
- National Center for Complementary and Alternative Medicine
- National Institute on Drug Abuse (NIDA)
- NIMH
- Organon
- Pamlab
- Pfizer
- Pharmavite
- Roche
- sanoffaventis
- Shire
- Solvay
- Synthelabo
- Wyeth
- Stanley Medical Research Institute
- Society of Biological Psychiatry
- Corcept
- Cyberonics
- Merck
- NIDA
- NARSAD
- Pharmacia Upjohn
- Predix
- Targacept
- NIMH, Notional Institutes of Health [NO1MH90003]
- NATIONAL INSTITUTE OF MENTAL HEALTH [N01MH090003] Funding Source: NIH RePORTER
Introduction: Insomnia symptoms, which are common in depression, have a significant impact on function and quality of life. However, little is known about the prevalence and associated features of insomnia symptoms in representative treatment-seeking patients with depression. Methods: Data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial were analyzed. STAR*D recruited 3,743 adult outpatients diagnosed with nonpsychotic major depressive disorder (MDD) from primary (n=18) and psychiatric care (n=23) clinics across the United States. Baseline sociodemographic and clinical features were compared between those with insomnia symptoms (84.7%) and those without (15.3%). Results: The most common presentation was the simultaneous presence of sleep onset, mid-nocturnal, and early morning insomnia symptoms (27.1%). Of these three types of insomnia symptoms, mid-nocturnal insomnia symptoms were the most commonly found alone (13.5%) and in combination with one or more other types (82.3%). Insomnia symptoms were associated with several indicators of a more severe depressive illness. Only a small proportion of participants with insomnia symptoms were receiving treatment for sleep disturbances at study initiation, and the vast majority of those receiving treatment still reported having insomnia symptoms. Conclusion: In outpatients who seek treatment for nonpsychotic MDD in typical clinical settings, insomnia symptoms are very common, undertreated, and indicative of a more severe depression. CNS Spectr. 2010;15(6):394-404.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据